Beyfortus (nirsevimab) / AstraZeneca, Sanofi, SOBI - LARVOL DELTA

Top 20 Research Studies of 2024 for Primary Care Physicians. (PubMed, Am Fam Physician) - "Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19. In average-risk infants, a single dose of nirsevimab reduces hospitalizations due to respiratory syncytial virus...Low-dose amitriptyline is effective as second-line therapy for irritable bowel syndrome...Phentermine-topiramate and GLP-1 receptor agonists are the most effective drugs for promoting weight loss...For patients who do not quit smoking after a trial of varenicline or combined nicotine replacement therapy, a higher dose of either drug can increase quit rates...Oral naltrexone and acamprosate are safe and effective treatments for alcohol use..."

Journal • Review • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Diabetes • Fatigue • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Nephrology • Novel Coronavirus Disease • Obesity • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • Sinusitis • Type 2 Diabetes Mellitus

Challenges and Limitations of Current RSV Prevention Strategies in Infants and Young Children: A Narrative Review. (PubMed, Vaccines (Basel)) - "Recently, RSV prevention has advanced with the introduction of nirsevimab, a long-acting monoclonal antibody, and the RSV preF vaccine for maternal immunization... Despite substantial progress, current RSV prevention strategies leave critical gaps, particularly for older infants and underserved populations. There is a pressing need for next-generation vaccines, enhanced pharmacovigilance, and equitable global implementation to ensure sustained and inclusive RSV protection."

Journal • Review • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis. (PubMed, Asian Biomed (Res Rev News)) - "For decades, monthly palivizumab injection has provided passive immunization for high-risk infants and has demonstrated efficacy in reducing RSV-related hospitalizations, while breastfeeding has been known to protect against severe RSV-LRTI...Additionally, long-acting RSV monoclonal antibodies (Nirsevimab) provide season-long protection with a single dose for infants during the first RSV season, reducing both medically attended RSV-LRTI and hospitalizations by approximately 70%-80% in infants during their first RSV season. Consequently, in 2024, the Strategic Advisory Group of Experts (SAGE) recommended that countries introduce maternal RSVPreF vaccination and/or RSV monoclonal antibodies for infant RSV prevention. Many countries have already adopted these interventions, demonstrating cost-effectiveness of monoclonal antibodies."

Journal • Review • Cardiovascular • Heart Failure • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Severe RSV Infection Occurring at the End of Nirsevimab's Protection Window: A Case Report. (PubMed, Case Rep Pediatr) - "Additionally, co-infection with hRV may have contributed to disease severity. Although nirsevimab remains a highly effective preventive tool, this case highlights the potential for waning immunity near the end of the protection window and suggests that ongoing surveillance is essential to optimize immunization strategies, particularly in regions with prolonged RSV seasons."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy. (PubMed, Front Public Health) - "Real-world data from the Tuscany birth cohort (N = 21,017) experiencing their first RSV season in the 2023/2024 season were used to calculate the net benefit and benefit cost ratio (BCR) of three possible nirsevimab prophylaxis strategies compared with prophylaxis practices at the time of the study, which includes the use of palivizumab in eligible infants. Universal prophylaxis strategies with nirsevimab, targeting all infants during their first RSV epidemic season, substantially reduce hospitalization burdens without increasing economic pressure on the healthcare system. Although alternative strategies are more cost-effective, they prevent fewer hospitalizations, emphasizing the public health value of broader prophylaxis approaches."

HEOR • Journal • Real-world evidence • Respiratory Diseases • Respiratory Syncytial Virus Infections

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment. (PubMed, Infect Dis Ther) - "RSV is a leading cause of severe lower respiratory tract infections and is one of the primary causes of hospitalization in high income countries and death among children aged ≤ 1 year in lower income; bivalent Stabilized Prefusion F Subunit Vaccine (RSVpreFV) for maternal immunization proves to be effective in preventing RSV infections, avoiding severe disease. The modelling exercise shows that the complementary strategy of maternal vaccination with palivizumab or nirsevimab are both dominant (better health outcomes with lower costs) on monoclonal antibodies alone; the sensitivity analysis confirms that the complementary strategies in most of the simulation remain dominant or cost-effective adopting a low threshold for the willingness to pay; finally the complementary strategies are also sustainable, owing to a limited impact on the current national budget for vaccines."

HEOR • Journal • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK. (PubMed, Infect Dis Ther) - "Universal immunisation with nirsevimab for all infants during their first RSV season could significantly reduce both the health and economic burden of RSV in the UK. This strategy is more effective than MI, particularly in reducing severe RSV outcomes and protecting infants born outside the RSV season, thus offering substantial benefits across the infant population."

HEOR • Journal • Critical care • Respiratory Diseases • Respiratory Syncytial Virus Infections

A paradigm shift in post-bronchiolitis recurrent wheezing: the dual impact of COVID-19 and Nirsevimab (ERS 2025) - No abstract available

Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants. (PubMed, JAMA Netw Open) - "The Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention recommend seasonal administration of maternal vaccine (MV) or nirsevimab to protect infants in the first year of life from respiratory syncytial virus (RSV) infections...Intervention use may be optimized by restricting administration to select months. Further study is needed to assess transmission dynamics to refine cost-effectiveness outcomes."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network. (PubMed, Pediatrics) - "In a large, diverse pediatric primary care network, 35% of eligible children received RSV prophylaxis despite near universal availability. Practice site, age, race, COI, and insurance were associated with nirsevimab receipt. Future work should examine the drivers of these disparities to inform quality improvement work to protect all infants from RSV."

Journal • Pediatrics • Respiratory Diseases

Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital. (PubMed, Pediatr Pulmonol) - "Nirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study also highlights shifts in RSV seasonality trends influenced by the COVID-19 pandemic, highlighting the need for ongoing surveillance to adapt public health strategies."

Clinical • Journal • Retrospective data • Critical care • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Newborn RSV immunization rates and reasons compared to family COVID-19 and influenza immunization status. (PubMed, BMC Pediatr) - "Parental acceptance of RSV immunization was driven by protective instincts for newborns and familiarity with RSV as a disease. Hesitancy toward COVID-19 vaccination stemmed largely from concerns about effectiveness and confusion around immunization/vaccine purpose. Trust in medical professionals influenced decision-making, though participants lacked a consistent source of immunization information. Improved public education on immunization efficacy and centralized access to trustworthy information may enhance immunization uptake and address ongoing hesitancy across all pediatric immunizations."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab Uptake in a Pediatric Primary Care Network During the 2023-2024 RSV Season. (PubMed, JAMA Netw Open) - No abstract available

Journal • Pediatrics

Pediatric respiratory syncytial virus rehospitalization rate - a retrospective observational study from Switzerland. (PubMed, BMC Pediatr) - "Same-season RSV rehospitalizations were exquisitely rare. Routine administration of a dose of a monoclonal antibody for protection against a same-season rehospitalization does not appear to be generally warranted. The majority of patients with subsequent season readmission would be covered by the current recommendations in Switzerland as they had pre-existing conditions making them eligible for second-season RSV prophylaxis."

Journal • Observational data • Retrospective data • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial virus among Chinese infants: a modelling study. (PubMed, Expert Rev Vaccines) - "Tripling the coverage could avert 183 282 RSV-ALRI cases (59 713 hospitalized), 506 deaths and 17 425 QALY loss, saving $231 million. Nirsevimab introduction could effectively mitigate RSV-ALRI burden in Chinese infants, and enhanced coverage is recommended to maximize the public health benefits."

Journal • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Early Nirsevimab Administration During Hospitalization for RSV Bronchiolitis may Reduce Disease Severity in Non-immunized infants: A Descriptive Study. (PubMed, Arch Bronconeumol) - No abstract available

Journal • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory Syncytial Virus Vaccination Acceptance: The Importance of Asking "Why?". (PubMed, J Pediatr Clin Pract) - No abstract available

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab To Prevent Serious Healthcare-Associated RSV Infection During Prolonged Birth Hospitalization (IDWeek 2025) - No abstract available

Clinical • Infectious Disease • Respiratory Syncytial Virus Infections

Impact of Nirsevimab on bronchiolitis: reduction in hospitalizations and severity (ERS 2025) - No abstract available

Clinical • Pulmonary Disease • Respiratory Diseases

Viral Bronchiolitis in Infants in the Era of Targeted Therapies: What Now and What's Next? (PubMed, Pediatr Pulmonol) - "Understanding and addressing the causes of poor adherence to bronchiolitis guidelines is critical. Future research should aim to integrate evidence-based treatments with options for personalized adjustments. Updated guidelines should reflect emerging interventions and provide rational management pathways until robust evidence from new studies becomes available."

Journal • Review • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Characteristics of Children Aged 0 to 23 Months Hospitalized With Respiratory Syncytial Virus. (PubMed, Pediatrics) - "UMCs were more frequently identified among hospitalized children aged 12 to 23 months compared with children 0 to 2 months; prolonged ICU admission was associated with airway abnormalities, CVD, Down syndrome, and feeding tube dependence."

Journal • Cardiovascular • Critical care • Developmental Disorders • Genetic Disorders • Respiratory Diseases • Respiratory Syncytial Virus Infections

Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. (PubMed, Pediatrics) - "Nirsevimab was highly effective in protecting infants against RSV-associated LRTD as well as against milder RSV infection. Nirsevimab-immunized infants with RSV LRTD had significantly fewer medical encounters and were less likely to be hospitalized than were nonimmunized infants."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Factors Influencing Parental Decisions on Respiratory Syncytial Virus Immunoprophylaxis. (PubMed, J Pediatr Clin Pract) - "The desire to protect their infant from illness was the primary reason for parental RSV immunization intent, while the primary reasons for not immunizing were lack of availability, lack of provider recommendation, and the perception that the immunizations are too new. Ensuring availability and strong recommendations may improve immunization uptake."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

New therapies for old viruses: when everyone gets something wrong (PubMed, Epidemiol Prev) - "The respiratory syncytial virus causes numerous respiratory infections in children, with particularly severe manifestations during the first months of life, especially in premature infants or those with pre-existing clinical conditions.In Italy, the introduction of nirsevimab, a monoclonal antibody that is more practical and potentially usable in a broader population compared to the previous palivizumab, has highlighted several critical issues in the management of the prevention system. A national agreement was reached, allocating funds for an immunization campaign covering approximately 75% of newborns, corresponding to the availability guaranteed by the manufacturer. Additionally, a solidarity distribution mechanism was introduced, allowing up to 20% of doses to be shared among regions to protect the most vulnerable individuals.Despite the campaign started with the onset of the epidemic season, challenges persist in organizing procurement processes and managing..."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants. (PubMed, World J Pediatr) - "The burden of RSV disease in young children is substantial, especially in those < 2 years old, accounting for up to 47% of bronchiolitis and pneumonia admissions in children < 6 months. The administration of a single dose of nirsevimab may be offered to infants at birth for the prevention of RSV in Singapore."

Journal • Review • Infectious Disease • Pediatrics • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections